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Downloapose: To find molecular markers from expression profiling data to predict recurrence of laryngeal
after radiotherapy.
erimental Design: We generated gene expression data on pre-treatment biopsies from 52 larynx
patients. Patients developing a local recurrence were matched for T-stage, subsite, treatment, gen-
d age with non-recurrence patients. Candidate genes were then tested by immunohistochemistry on
material from a second series of 76 patients. Both series comprised early stage cancer treated with
herapy alone. Finally, gene expression data of eight larynx cancer cell lines with known radiosen-
were analyzed.
ults: Nineteen patients with a local recurrence were matched with 33 controls. Gene sets for hyp-
roliferation and intrinsic radiosensitivity did not correlate with recurrence, whereas expression of
tative stem cell marker CD44 did. In a supervised analysis, probes for all three splice variants of
on the array appeared in the top 10 most significantly correlated with local recurrence. Immuno-
hemical analysis of CD44 expression on the independent validation series confirmed CD44's pre-
e potential. In 8 larynx cancer cell lines, CD44 gene expression did not correlate with intrinsic
ensitivity although it did correlate significantly with plating efficiency, consistent with a relation-
ith stem cell content.
clusions: CD44 was the only biological factor tested which significantly correlated with response
iotherapy in early stage larynx cancer patients, both at the mRNA and protein levels. Further studies
eded to confirm this and to assess how general these findings are for other head and neck tumor










ativelyincidence of larynx cancer in the United States is
d 4.5 cases per 100,000 per year (1). The 5-year rel-
urvival percentage for localized disease has been sta-
around 70-80% for the last 20 years (1). In early
eal cancer, radiotherapy is an effective treatment
lity, with local control rates between 80-90% for
ors (2). Partial laryngectomy or CO2 laser resection
ternative treatments with comparable survival rates,
gh when used as salvage after a failed radiotherapy
they have a higher complication rate (3). Treatment
is mainly based on the estimated functional out-s: Departments of 1Experimental Therapy, 2Radiation
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on May 8, 202clincancerres.aacrjournals.org ded from and the preferences of the clinician. It would there-
e useful to predict beforehand which patients will
it from radiotherapy. Prediction of resistance is also
to be increasingly useful in the development of bio-
l modifiers which increase the effects of radiation,
ing an alternative treatment for resistant tumors.
ortant clinical factors associatedwith local recurrence
adiotherapy are tumor stage, tumor size, radiotherapy
n size and year of treatment (4). Treatment choice is
ainly based on T-stage (5), although this is still a rel-
poor indicator of survival (6). Since clinical factorsrtment of Otorhinolaryngology - Head and Neck Surgery and
l Biochemistry, University of Turku, Finland
upplementary data for this article are available at Clinical Cancer
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Treatment choice for larynx cancer is based on clin-
ical factors such as T-stage, but these are imprecise indi-
cators of response. Having robust methods to predict
outcome of a particular therapy would be extremely
valuable, allowing a more rational treatment choice
which should lead to greater tumor cell kill and also
spare patients from toxic and ineffective therapies. Such
predictors should include biological factors as well as
clinical factors, given the heterogeneity in tumor biolo-
gy even for patients presenting with similar sites and
stages. The present study employed gene expression pro-
filing in a series of larynx cancers and validated the result
in a second similar series using immunohistochemistry.
The principle predictor for outcome after radiotherapy
was CD44, a putative stem cell marker. In addition, this
study sheds light on potential mechanisms of radio-
resistance, which could lead to the design of targeted
drugs for combining with radiation.
de Jong et al.
Clin C5330
Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 t provide an accurate prediction, it is likely that recur-
of a tumor can partly be explained by tumor biology.
biological processes known to influence response to
herapy are intrinsic radiosensitivity (7), hypoxia (8)
population (9). For each of these processes, individ-
arkers (mainly immunohistochemical) have been in-
ated and found to be of predictive value (10–12),
gh none have been sufficiently validated or are in
e use. Since many genes are involved in each process,
ition to single markers representing these processes,
markers (gene sets) for hypoxia (13, 14), intrinsic ra-
sitivity (15–17) and repopulation (18) have also
defined. Another factor more recently hypothesized
y a role in response to therapy is the number of stem
ultimately determining repopulation of the tumor
0) and so eradication of this subpopulation is of
importance.
date, no studies have investigated all these processes
taneously. Microarrays have been used to measure
expression (mRNA) on a genome wide scale, and
principlemonitor all the above-mentioned processes
rrently. However, only one microarray study with 14
ts has been carried out for patients treated with radio-
y alone (21). Several expression profiling studies
een carried out on patients treated with radiotherapy
bination with surgery or chemotherapy (22–26).
ver, these have often included heterogeneous groups
ients and cannot address the question of factors affect-
e response of laryngeal cancer to radiation alone.
r objective was to find a gene expression profile that
curately predict local recurrence after radiotherapy in
ogeneous group of patients with early laryngeal carci-
. We chose to study early stage tumors, since these are
to be more homogeneous than advanced tumors andancer Res; 16(21) November 1, 2010
Research. 
on May 8, 202clincancerres.aacrjournals.org Downloaded from chnically easier to treat,minimizing the chance of geo-
ical misses. Treatment failure is then highly likely to be
biological rather than technical factors. In addition to
more insight into the molecular processes underlying
ent failure, accurate prediction would enable treat-
to be individualized, leading to increased survival
ss unnecessarymorbidity.We studied two series of ear-
ge larynx cancer patients treated with radiotherapy
. The first was a test series of frozen tumor specimens
o study global gene expression to discover predictive
rs for local control, which were then validated on a
d series by immunohistochemistry.
rials and Methods
studies reported here were done with approval of the
Medical Ethics Committees.
expression series
ients. Fifty two patients were recruited from five dif-
institutes in The Netherlands and were eligible if
ad been treated for a T1 or T2 larynx carcinoma
upplemental Table 1), and pre-treatment fresh fro-
mor material was available. Patients were treated
en 1997 and 2005, and staging was done either clin-
or with a CT-scan. Because patients with small
rs did not have a CT-scan, tumor volumes could
e measured for the whole group. Treatment was ra-
erapy alone with curative intent, applying fraction-
schemes standard in each of the five centers. To
are different radiotherapy schedules, the equivalent
n 2-Gy fractions (EQD2) was calculated for every pa-
ith the formula: EQD2 = D × (d + α/β)/(2 + α/β),
D is the total dose, d the given fraction dose, the α/β
as assumed to be 10 Gy. Recurrence was defined as a
ogically proven local tumor recurrence within two
of the initial treatment, to ensure the analysis of true
ences rather than second primaries. Since we planned
dy amatched series, for every patient with a recurrence
ed to include two controls, with a recurrence-free
-up of at least two years andmatched for the institute
ere treated in, T-stage, subsite, gender and age. There
no significant differences between groups with and
ut local recurrence in age, gender, subsite, T-stage,
ose, fraction size, tumor percentage or RNA quality
lemental Table 1).
A isolation. All biopsies were snap frozen in liquid ni-
. Around 30 slices of 30 μm were deposited in RNA-
ampro scientific). Before and after these 30 slices
sections were taken that were subsequently assessed
experienced pathologist, who scored differentiation
mor percentage. Only biopsies containing on aver-
ore than 50% of tumor cells were included. The tu-
aterial in RNA-Bee was processed using the Qiagen
sy mini and RNase-free DNase kits. Total RNA was
d and DNAse treated using spin columns according
manufacturers instructions. The Agilent 2100 bioa-
r was used to assess the integrity (intactness) of theClinical Cancer Research
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 Samples with an RNA Integrity Number (RIN) under
with no obvious 18S and 28S peaks were discarded.
e expression. cDNA was made from one microgram
al RNA and amplified into aRNA with T7-mRNA
script-III amplification kit (Invitrogen). Only ampli-
n yields over 1000-fold with a 1 kB smear on a gel
ccepted. Hybridization to microarray slides was per-
d at our Central Microarray Facility (http://microarrays.
l). All samples were hybridized to Illumina bead
(v3 Illumina beads) and subsequently scanned using
lumina scanner. Each Illumina array consists of
ron silica beads covered with oligos containing over
0 transcript probes per sample, representing around
0 known genes. Each transcript probe was represented
than 20-fold per array and final data were averaged
ch probe. Fluorescence intensities were measured
he Illumina scanner and averaged per probe.
a analysis. The dataset was transformed (variance
izing method (ref. 27)) and normalized (robust
method) with the Lumi (28) package for R, version 2.8
http://www.R-project.org). If, for a specific probe, no
t had a value above background levels, that probe
ltered out. Gene sets for hypoxia, proliferation, radio-
ivity and stem cells were tested (13–16, 18, 30, 31).
ne identifiers were used to map the genes in a set to
notations of the Illumina array. For gene sets with
n weights contributing to the endpoint (as described
original publications), Pearson correlations were cal-
d against the weights of a gene set for each patient.
lso allowed assessment of gene sets which included
both positively and negatively correlating with out-
For gene sets without weights (each gene assumed
tribute equally), the average expression of the genes
set was calculated. For these signatures, all genes in













on May 8, 202clincancerres.aacrjournals.org Downloaded from earson or average values were then used in a logistic
sion with local recurrence data. In order to give com-
le odds ratios, some Pearson correlations were multi-
by 5 or 10, which does not change the P-values but
y provides a better comparison of odds.
ddition to this hypothesis-driven analysis, a data-
analysis was performed with Biometric Research
h (BRB) array tools (NIH, http://linus.nci.nih.gov/
raytools.htm). Genes were first filtered by including
s where at least 20% of samples had a minimum fold
e greater than 1.35 and aP-value for log-ratio variation
0.01. The filtered set was entered in a nearest centroid
l that finds genes that best predict local recurrence.
significantly different between the patients with and
ut recurrence at the P < 0.01 significance level were
or class prediction. The leave-one-out cross-validation
d was used to compute mis-classification rates.
nohistochemistry series
ients. Of the patients included in the mRNA expres-
icroarray series, paraffin embedded material for im-
histochemistry (IHC) was used from two of the five
tes (Amsterdam and Groningen). This small subset
cases was used to confirm gene expression values by
second matched series of 76 patients was used as an
endent validation series of our findings from the gene
sion study. Paraffin embedded biopsies were used to
cores for a tissue microarray (TMA). The construction
TMA and the patient characteristics were described
usly (10). Briefly, the patients were predominantly
with stage T1 and T2 glottic tumors given a median
y in 2Gy fractions (Supplemental Table 2).
unohistochemistry staining. Sections of 3 μm were
m either whole tissue blocks or the TMA andmounted



















ancer Res; 16(21) Nove
an Association for Ca5% CI)ell (CD44)(31) .4-172.3)
ell (Glinksky)(45) .3-42.2)
hypoxia (Chi) ×10(14) .1-46.6)
ia metagene (Winter)(13) .5-1225.2)
ell genes (various) excluding CD44 .4-129.7)
ensitivity (17), response .002-46.0)
ration (Shepard*) ×10 .2-12.2)
ic hypoxia (14) .1-3.8)
ensitivity (15) .03-9.4)
ration (18) .03-26.1)ife 6.4-7.1 0.95 0.9 (0
E: Range: lowest to highest value of either Pearson correlations against the weights of a gene set or, for gene sets without
hts, the average expression (log2 scale) of the genes in the set. OR: odds ratios with corresponding confidence intervals and
lues were generated from a logistic regression of Pearson or average values of the gene sets with local recurrence data. In
r to give comparable odds ratios, some Pearson correlations were multiplied by 5 or 10 (not changing the P-values).
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 hofen Germany)-coated glass slides. Slides were de-
inized in xylene and rehydrated in ethanol. Antigen
al comprised boiling the slides in a microwave oven
ate (pH 6.0) for 15 minutes. Endogenous peroxidase
locked with 0.3% hydrogen peroxidase for 30 min-
lides were incubated with a mouse monoclonal anti-
s against CD44 (156-3C11; dilution 1:200; Cell
ing Technology, Danvers, MA) and CD44v6 (clone
8; dilution 1:8000; Bender Medsystems, Vienna, Aus-
r 1 h at room temperature. Detection was performed
AMHRP (dilution1:100) andGARHRP (dilution 1:100),
ized by 3′3-diaminobenzidinetetra-hydrochloride
unterstained with haematoxylin.
unohistochemistry scoring. The percentage of tumor
taining positive for CD44 was scored as well as the
ity of staining (low or high). A CD44 staining score
alculated by adding the percentages of positive low
igh intensity cells, weighted by factor of 1 and 2 re-
vely. This weighted score reflects total CD44 protein
than total percentage positive cells, for better com-
n with total mRNA from the microarray analysis. For
t of patients in which concordance between mRNA
HC was tested, all slides were analyzed indepen-
by two teams, each consisting of a pathologist
and JvdW) and a scientist. Slides scored differently
two teams were discussed at a conference micro-
to reach consensus. Before consensus, the inter-
er correlation for CD44 scores was 0.75 (P < 0.001;
emental Fig. 1). For the TMA series of 76 patients,
g was done by one team. Pearson correlations were
ated between mRNA levels and IHC scores. For the
nalysis, associations between CD44 expression and
ecurrence were compared using a logistic regression
l. P-values of <0.05 were considered statistically sig-
t. Statistical analysis was performed with SPSS 16.0
indows (SPSS Inc., Chicago, IL).
x cancer cell lines
l culture. The larynx cancer cell lines UT-SCC-6A,-8,-
,-19B,-22,-23 and -42A from the University of Turku
nd) were cultured in DMEM with 10% FBS, 1%
, 1%L-glutamine and 1% penicillin-streptomycin.
ation was available on plating efficiency and radio-
ivity for all cell lines (published and unpublished
(refs. 32–34).
e expression. For each cell line, 1 × 106 cells were
d with ice cold PBS at approximately 50% conflu-
nd then collected in RNA-Bee. Illumina microarray
ere generated using the same methods and materi-
described above for the tumor biopsies.
lts
expression
e expression analysis. Exclusion of probes that did
xceed background expression in any patient left
4 probes for analysis. Gene expression signatures
poxia, intrinsic radiosensitivity, repopulation andancer Res; 16(21) November 1, 2010
Research. 
on May 8, 202clincancerres.aacrjournals.org Downloaded from cells were analyzed in a logistic regression (Table 1).
utative stem cell marker CD44 was the most signifi-
ith an unrelated stem cell signature as second most
icant. A third stem cell signature not including CD44
upplemental Table 3) was fifth of the 12 signatures
but was not significant. After multiple testing cor-
n (Bonferroni), only CD44 expression remained sig-
nt (P = 0.024). Comparative histograms of CD44
ssion illustrate the higher expression in recurrences
s cures (Fig. 1A). When patients were divided into
groups of low, medium and high CD44 expression,
o that there were equal numbers of recurrences in each
, the odds of recurrence (number of recurrences
ed by number of non-recurrences for each group)
5.2 fold higher in the highest CD44 expression group
ared with the lowest (P = 0.003, Fig. 1B). Expression
te hypoxia genes was also associated with local recur-
, although significance was lost after correction for
ple testing. Radiosensitivity and proliferation genes
d no relationship with recurrence.CD44 expression predicts local recurrence. A, histograms of CD44
expression for patients subsequently cured (open bars) or those
uently suffering a recurrence (closed bars). B, odds of recurrence
atients are divided into three groups with increasing mRNA levels,
that each group contains equal numbers of recurrences. OR: odds
recurrence between highest and lowest CD44 expression groups.Clinical Cancer Research
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 r restriction of the dataset to those 8,317 probes that
d significant differences in expression between the
s, thus removing uninformative probes, we performed
-driven analysis for which genes best predicted recur-
When the univariate significance alpha level was set
0.01, 34 probes (18 up and 16 down-regulated in tu-
subsequently recurring) were found to be predictive
2). The most significant upregulated marker discrim-
g between cures and recurrences wasCD44 (P < 0.002).
he nearest centroid method only 23% of the patients
orrectly classifiedwith these 34genes. In addition, false
ery rates, as calculated by the Benjamini-Hochbergacrjournals.org
Research. 
on May 8, 202clincancerres.aacrjournals.org Downloaded from d, were high. However, despite the predictive weak-
f the signature as a whole, of note was that all three
s for CD44 that were present on the array appeared in
p 10 highest ranking upregulated genes. Two of the
s (variants 4 and 5)map to the constant and largest ex-
on 18), while variant 1 maps to the first variable exon
6). Expression of each probe was highly significantly
ated with expression of each of the other probes across
tumors (all P-values <0.001; 1 vs 3, 1 vs 5, 3 vs 5).
ddition to CD44, the remaining top ranking genes
Table 2 were most highly represented in a pathway
nt to “cell cycle, cellular development, cellular2. Data driven classifier, showing top 34 most significant genes, all with a P-value <0.01symbol t-value Parametric
e
Prob ID Desc iptionGULATED in recurrence−3.4 0.001 ILMN 1803429 CD44 molecule (Indian blood group), transcript variant 4
B12 −3.1 0.003 ILMN 1702168 hydro ysteroid (17-beta) dehydrogenase 12
1 −3.0 0.003 ILMN 1705066 BTB OZ) domain containing 11, transcript variant 1−3.0 0.003 ILMN 1713347 cell a hesion molecule with homology to L1CAM
−3 0.004 ILMN 1738589 mono lyceride lipase, transcript variant 1
−2.9 0.005 ILMN 1724658 BCL2 adenovirus E1B 19kDa interacting protein 3
−2.9 0.005 ILMN 1673676 sortin nexin 5, transcript variant 1
−2.8 0.006 ILMN 1778625 CD44 antigen (Indian blood group), transcript variant 1IN1 −2.8 0.007 ILMN 1754145 cell c cle associated protein 1, transcript variant 1
−2.8 0.007 ILMN 2348788 CD44 molecule (Indian blood group), transcript variant 52A −2.7 0.008 ILMN 1656621 chromatin modifying protein 2A, transcript variant 1
A4 −2.7 0.008 ILMN 1678678 solute carrier family 37 (glucose-6-phosphate transporter), member 4
2 −2.7 0.009 ILMN 1726769 CNDP dipeptidase 2 (metallopeptidase M20 family)
1 −2.7 0.009 ILMN 1730291 ATPa e, Na+/K+ transporting, beta 1 polypeptide, transcript variant 1−2.7 0.009 ILMN 1761829 hexok nase 1, transcript variant 1
VL −2.7 0.009 ILMN 2263466 acyl-Coenzyme A dehydrogenase, very long chain, transcript variant 1−2.6 0.009 ILMN 1775501 interleukin 1, beta
−2.6 0.01 ILMN 1751572 trans ucin-like enhancer of split 1 (E(sp1) homolog, Drosophila)-REGULATED in recurrence1 2.7 0.009 ILMN 1774256 prote se, serine, 21 (testisin), transcript variant 2
T4 2.7 0.009 ILMN 1730504 1-acy glycerol-3-phosphate O-acyltransferase 42.7 0.009 ILMN 1711862 ring f ger protein 7, transcript variant 3
2.7 0.008 ILMN 2218450 LSM1 homolog, U6 small nuclear RNA associated (S. cerevisiae)H2 2.7 0.008 ILMN 1786036 G pa h domain containing 2
A7 2.7 0.007 ILMN 1778673 golgi utoantigen, golgin subfamily a, 7, transcript variant 2
1 2.8 0.007 ILMN 1671116 chromosome 3 open reading frame 212.8 0.006 ILMN 1762003 trans cation protein 1
H2AC 2.8 0.006 ILMN 1768973 histone cluster 2, H2ac2.8 0.006 ILMN 1665554 subu it of RNA polymerase III transcription initiation factor, BRF1-like
1 2.9 0.005 ILMN 2232157 slowmo homolog 1 (Drosophila)
L1 3.0 0.004 ILMN 2142117 lysop ospholipase-like 1
55 3.0 0.003 ILMN 2348090 mitoc ondrial ribosomal protein L55, transcript variant 53.1 0.003 ILMN 1766573 telom rase RNA component on chromosome 3
1 3.2 0.002 ILMN 1663664 mitoc ondrial ribosomal protein S10
7 3.5 0.001 ILMN 1670752 KIAA 907A9 1 _ 0Clin Cancer Res; 16(21) November 1, 2010 5333
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 h and proliferation” (from Ingenuity Pathway Anal-
This pathway contained EGF, VEGF, and HRAS as
enes and of 35 genes on the pathway, 11 appeared
of top ranking genes (Supplemental Fig. 2).
protein level versus outcome
44 mRNA correlates with immunohistochemical
sion. Both frozen and paraffin embedded material
adily available from 20 tumors and used to compare
and protein expression. Antibodies were tested
st an epitope common to all CD44 variants and
pecific for the v6 variant. Figure 2 shows examples
44 staining. All tumors showed some expression
on average 24% of tumor cells staining with a low
ity and 52% with a high intensity) although the
g was heterogeneous in all cases. In tumors show-
lear differentiation pattern, the basal cell layers were
intensely stained than the more differentiated cells.
the CD44 and the CD44v6 immunostaining scores
ated significantly (P < 0.05) with the average for all
CD44 mRNA probe levels (Supplemental Fig. 3).
44 expression in the validation series. We next tested
er immunohistochemical expression of CD44 corre-
with clinical outcome. We used an independent
ed series of laryngeal cancers with patient character-
imilar to the test series. Patient characteristics of this
tion series, like the 52 patients in the test series, were
minantly male with a T1-2 glottic tumor and treated
adiotherapy alone (Supplemental Table 4). CD44
sion, assessed immunohistochemically for percent-
D44-positive cells weighted according to staining in-
y (see Materials and Methods), was significantly
ated with clinical outcome. Histograms of the IHC
showed higher CD44 protein expression in recur-
compared with cures (Fig. 3A). As before, when pa-
were divided into three groups with low, mediumancer Res; 16(21) November 1, 2010
Research. 
on May 8, 202clincancerres.aacrjournals.org Downloaded from igh CD44 expression, split to ensure equal numbers
urrences per group, the odds ratio for recurrence was
ld higher in the highest group compared with the
t (P = 0.005, Fig. 3B). These data on protein expres-
hus confirm the mRNA expression data.
x cancer cell lines
ddition to cellular radiosensitivity, the effectiveness
tionated radiotherapy can be determined by micro-
nmental factors such as hypoxia, repopulation rates
g therapy, and the fraction of stem cells. As a first
n attempting to dissect the role played by CD44 on
factors, we studied a series of larynx cancer cell lines
r well controlled in vitro conditions. As shown
. 4, CD44mRNA levels (average for the three probes)
ated significantly with plating efficiency (P = 0.03).
plating efficiency has been correlated with tumor ini-
capacity in several studies, this is consistent with
being a stem cell marker in this tumor type. In the
experiments, CD44 expression did not correlate with
sic radiosensitivity in these 9 larynx cancer cell lines
ue = 0.71). None of the three CD44 probes individu-
owed a correlation with radiosensitivity, while two
f three CD44 probes show a significant correlation
lating efficiency (Supplemental Table 4). These data
that CD44 expression is not monitoring intrinsic
ensitivity but rather the fraction of stem cells.ssion
aim of this study was to find prediction markers for
l outcome of larynx cancer after radiotherapy using
expression profiling. We chose to study early stage
rs since these will be inherently less variable than
ced cancer both in terms of genetically differentExamples of CD44 immunohistochemistry. Staining, using antibody 156-3C11, against an epitope common to all CD44 variants, on the tissue
ray for three representative cores at two different magnifications (100× and 400×). Scorings for these cores were: A: 40% intensity I. B: 95%
y II. C: 80% intensity II.Clinical Cancer Research
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0799 pulations and variability in blood flow and hypoxia.
dition, delivery of the radiotherapy is less compli-
with less chance of geographical misses. Any recur-
are therefore likely to be due to inherent resistance
tumor cells. Secondly, we chose to match recurrent
on-recurrent patients for the most important known
l variables (T-stage, subsite, treatment, gender and
so that these would not be confounding factors in
alysis.
he test series, we studied the expression of several
genes monitoring biological processes known to in-
ce the outcome of radiotherapy. We found that
, chosen as a stem cell marker, showed the most sig-
nt correlation with local recurrence. Expression of
monitoring proliferation and intrinsic radiosensitiv-
wed no correlation with outcome. A gene set defin-
ute hypoxia showed a trend, although not significant
corrected for multiple testing. In a separate data-
analysis including over 8000 genes (after filtering








































on May 8, 202clincancerres.aacrjournals.org Downloaded from ion across the samples), the three probes for CD44
out high in the ranking list of genes correlating with
ence, one of the probes being the most significant of
es tested. This non-hypothesis-driven approach sup-
d the hypothesis-driven approach, indicating that
is a good predictor of outcome after radiotherapy
ese head and neck squamous cell carcinomas.
ermore, in an independent validation series, CD44
n expression measured immunohistochemically cor-
d significantly with outcome, such that higher CD44
were associated with a higher chance of local recur-
Since both these were matched series, results are in-
dent of the most important clinical predictors.
previous expression profiling study from our own
te on a series of 91 HNSCC patients treated with
rrent radiation and cisplatin, CD44 was higher in tu-
from patients which subsequently developed a recur-
although this did not reach significance (P = 0.08)
5). Kawano et al found CD44s and CD44v6 staining
ated with prognosis in a series of 57 patients treated
urgery and radiotherapy (35). Zhao et al analyzed
ns after surgery for 112 HNSCC patients and found
D44v6 presence in these margins, detected with
nohistochemistry, was predictive of recurrence
Wang et al. (37) found that one CD44 isoform
was associated with reduced disease free survival
SCC. These, together with the present study, support
expression as a negative predictive factor.
chose CD44 as a stem cell marker for HNSCC, since
et al. (31) showed that CD44 positive cells in this
r type were up to an order of magnitude more tumor-
than CD44 negative cells. These data indicated that
positive cells are enriched in cancer stem cells. How-
our and other (38) IHC studies showed a relatively
verage percentage of cells staining for CD44, incon-
t with a small minority stem cell fraction. We and
also observed a gradient of CD44 staining, where
n more basal-like areas stained more positively than
n the more differentiated areas. Such patterns may
more stem like properties of cells in the basal-like
analogous to that in normal epithelia.
uming that CD44 has a causal role in determining
ance of recurrence and is not simply an indirect
r for stem cell content or another unknown process,
are several possible explanations for this role in the
functions of CD44. CD44 is a transmembrane gly-
tein with many transcript variants and has hyaluro-
an extracellular matrix protein, as a ligand (39).
s functions of CD44 have been described, including
oting tumorigenesis, cell motility and invasion.
, when activated by ligand, can act as a co-receptor
eral membrane receptors, triggering various intracel-
ignalling pathways. In one of these, CD44 acts as co-
or for the ErbB family which can lead to activation
PI3K/AKT pathway, a pathway known to promote
al after cytotoxic damage, including after irradiation.
uggests a possible link between CD44 expression and
sic radiosensitivity. However, we did not find aCD44 IHC predicts local recurrence. A, histograms of CD44 IHC
r patients subsequently cured (open bars) or those subsequently
g a recurrence (closed bars). B, odds of recurrence when patients
ded into three groups with increasing IHC scores, split so that
oup contains equal numbers of recurrences. OR: odds ratio of
nce between highest and lowest CD44 expression groups.Clin Cancer Res; 16(21) November 1, 2010 5335
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panel of larynx cancer cell lines. Alternatives there-
eed to be sought to explain the relationship between
expression and radiocurability.
er possibilities are links with hypoxia or repopulat-
ility, both known to influence radiotherapy out-
. We found that CD44 expression correlated with
sion of acute hypoxia genes (Supplemental Fig. 4)
trend (P = 0.08) that expression of acute hypoxia
correlated with chance of recurrence. No significant
nship with expression of chronic hypoxia genes was
. This is consistent with other studies indicating that
ypoxic for relatively short times are more dangerous
hose chronically exposed to hypoxia (40, 41). We
no evidence of a link between CD44 expression
roliferation associated genes, or in this series be-
expression of proliferation genes and outcome. This
sistent with our earlier expression profiling studies
vanced head and neck tumors treated with radiother-
nd cisplatin, where proliferation genes were not
tive (25). Whether this is due to relatively slow re-
ation rates in these tumors, or because the signatures
t adequately monitor repopulation capacity during
ned radiotherapy is not known.
nal possible explanation is that CD44 expression
ors the number of stem or cancer initiating cells. It
ikely that all CD44-positive cells have stem cell pro-
s, considering the rather ubiquitous expression of
in normal tissues (www.genecards.org), and the
ely high average fraction of CD44-positive cells in
mors studied here and elsewhere (37, 38). However,
cancer stem cells are a constant subfraction of
-positive tumor cells, the stem cell fraction
mor initiating fraction) will be directly correlated
he CD44-positive fraction. In the current study, this
n varied by a factor of around 3. Based on Poisson
ics, such a three-fold change in the effective number
s which need to be killed by radiation would lead to
olute change in the cure probability of around 30%;ancer Res; 16(21) November 1, 2010
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on May 8, 202clincancerres.aacrjournals.org Downloaded from surviving cell on average would lead to 37% cure
bility, whereas 3 surviving cells on average would
o a 5% cure probability. It is therefore possible that
lationship between cure and CD44 expression is a re-
n of the number of cancer initiating cells needed to
led. This is independent of whether the putative stem
re more or less radioresistant than bulk tumor cells.
s contention is supported by the cell line data where
expression correlated significantly with colony
ng efficiency of unirradiated cells (and not with ra-
sitivity). This suggests a correlation with cancer ini-
g properties, since several studies have shown a
ation between in vitro plating efficiency and the
er of cells required to produce tumors in animals
4). In addition, the Glinsky signature (45), a puta-
em cell signature, also showed a strong trend with
me in the test series (Table 1). This BMI-1-driven sig-
was derived by comparing primary and metastatic
te cancer. We performed an Ingenuity pathway anal-
n this 11-gene signature, also including CD44. The
significant pathway resulting from the analysis
ed a link between the Glinsky genes and CD44
gh an interaction with TGFB1 (supplementary Fig. 2).
not definitive, these data support the notion that
is in some way monitoring stem cell capacity.
ious CD44 isoforms have been described with differ-
nctions (39). In the present study, correlations with
me were found with mRNA probes for one of the
nt regions, and with an antibody against a constant-
ressed epitope. Whether variant isoform expression
provide better prediction or understanding of fail-
eds further study.mary and Conclusion
44 expression, both at the mRNA and protein levels
ependent patient series, correlated with the proba-
of recurrence after radiotherapy for early stage larynxCorrelation of plating efficiency (A) and radiosensitivity (B; as measured by area under the survival curve (AUC)) with CD44 mRNA levels
ed over the 3 probes).Clinical Cancer Research
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tors the cancer stem cell fraction or that CD44
sion monitors the hypoxic fraction. It will be impor-
distinguish these two possibilities, since interventions
rease cure in patients with high CD44 expressing tu-
will depend on themechanism (attacking hypoxia, or
ing CD44 itself, or its downstream pathways, or other
ell specific pathways). Predicting outcome is important
to spare patients ineffective and toxic therapies. It will
ally or more valuable to provide alternative therapies
tients with resistant tumors. It is likely that CD44 ex-
on, measured with standard immunohistochemical
haps PCR-based assays will contribute to better out-
prediction, and the next steps will be to confirm me-
sms and design effective interventions against the
quences of this over-expression. The present data sug-
at the association between CD44 and radioresponse
s an increased number of cancer initiating cells that
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